Table 2.

Biodistribution p(TETA/CBA)-PEG

Formulation	w/w	Lung	Liver	Spleen	Kidney	Heart	Tumor
25% TCP	3	2.03 ± 0.94	14.78 ± 5.14	0.72 ± 0.78	2.02 ± 0.88	0.33 ± 0.67	0.61 ± 0.44
50% TCP	3	2.69 ± 1.30	14.67 ± 10.08	1.18 ± 0.39	0.27 ± 0.21	0.01 ± 0.00	0.32 ± 0.11
75% TCP	3	1.01 ± 2.23	9.35 ± 7.19	4.69 ± 5.99	0.46 ± 0.66	0.02 ± 0.00	0.35 ± 0.28
100% TCP	3	4.26 ± 3.28	10.59 ± 9.38	3.35 ± 1.69	0.88 ± 0.75	0.54 ± 0.99	1.37 ± 1.09
25% TCP	0.5	0.17 ± 0.10	0.22 ± 0.12	0.35 ± 0.07	0.16 ± 0.08	0.01 ± 0.02	0.52 ± 0.03
50% TCP	0.5	0.03 ± 0.01	0.14 ± 0.03	0.16 ± 0.07	0.01 ± 0.01	0.00 ± 0.00	0.30 ± 0.08
75% TCP	0.5	0.23 ± 0.03	0.22 ± 0.13	0.35 ± 0.06	0.08 ± 0.09	0.01 ± 0.02	0.52 ± 0.05
100% TCP	0.5	0.18 ± 0.11	0.63 ± 0.27	0.34 ± 0.15	0.14 ± 0.11	0.02 ± 0.00	0.24 ± 0.07

^*Values are shown as percent injected dose (% ID) 48 hr post-injection and represent the mean ± standard deviation (mean ± SD; n=5).